Biosyngen, a biotechnology company headquartered in Singapore that focuses on unmet therapeutic needs in cancer patients. Biosyngen develops first-in-class immunotherapy-based strategies to provide cancer patients with innovative drugs, overcoming refractoriness to standard-of-care treatments. Over the last eight years, Biosyngen has made remarkable achievements in developing a unique portfolio to target multiple solid tumors with proprietary designed cytotoxic T-cells including next-gen CAR-T, TCR-T and TILs to halt the progression of life-threatening advanced solid tumors. Biosyngen has established locally largest GMP facility in Singapore and China to serve patients globally. Biosyngen intends to be a global leader worldwide, having already established strategic collaborations with the most prestigious cancer centers. Bioyngen has secured 8 FDA and NMPA approved INDs, with two fast-track designations, and 2 phase 2 clinical trial clearances targeting a wide range of solid tumors.